Mark C. McKenna - 01 Feb 2024 Form 3 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Role
Director
Signature
/s/ Heidy King-Jones, as Attorney-in-Fact
Issuer symbol
SYRE
Transactions as of
01 Feb 2024
Net transactions value
$0
Form type
3
Filing time
05 Feb 2024, 17:25:26 UTC
Previous filing
21 Aug 2023
Next filing
08 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SYRE Stock Option (Right to Buy) 01 Feb 2024 Common Stock 477,000 $10.39 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents a right to purchase 477,000 shares of the Issuer's common stock, one quarter of which will vest and become exercisable on November 22, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer.

Remarks:

Exhibit 24 - Power of Attorney